Citius Pharmaceuticals Inc (CTXR) Stock Price, Quote & News

Company Profile

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli...

Industry: Biotechnology

Sector: Healthcare

Phone: 908 967 6677

Website: citiuspharma.com

Address:

11 Commerce Drive, First Floor, Cranford, United States

StockScanners Mar. 14 at 5:48 PM

$CTXR keep watch if this holds above .92

0 · Reply

topstockalerts Mar. 13 at 7:30 PM

$CTXR Traders tend to watch this one around company announcements because it’s had headline driven spikes before. When volume expands the move can build quickly.

0 · Reply

GJ_Rockabilt Mar. 13 at 6:55 PM

$CTXR What happened? Did CTXR Buy $EONR ?

0 · Reply

donein12 Mar. 13 at 2:42 PM

$CTXR Don't know what the price movment is from , but there is a reason for everything. There is no news. Volume is not high enough to suggest anything.

1 · Reply

Stock_Catcher Mar. 13 at 2:36 PM

$CTXR Riding the 9

0 · Reply

McNallieMoney Mar. 12 at 1:08 PM

$CTXR check out this interview!!! https://www.youtube.com/watch?v=r11VuZLKsXs

1 · Reply

TwongStocks Mar. 12 at 11:37 AM

$CTXR Clip from the D Boral webinar yesterday, regarding Mino-Lok. https://dl.sndup.net/yhchh/2026-03-11_ML_clip.mp3 “Somewhere in the next couple of months, I'm hoping that we'll get…a decision out of the Agency, whether it's that we can file or we may have to do a repeat something in this process. We don't know that yet, that's still under discussion.” AFAIK, this might be the first time that Leonard acknowledged the possibility that they may have to run another trial for Mino-Lok. The analysts hypothesized if they had to run a 2nd study, it would potentially involve 150 patients, 18-24 months, and $10M-$12M. Leonard replied that he was "in the ballpark with that." Now we have a better idea of what they ware waiting on. Confirmation from the FDA on whether they can file an NDA for Mino-Lok or if they have to do a 2nd study.

2 · Reply

900fix Mar. 11 at 7:56 PM

$CTXR Can't believe Lenny is pushing Mino-Lok again. He slow walked and scammed everyone with this. He should have been locked up. Don't fall for it.

1 · Reply

ImmxBeliever Mar. 11 at 5:10 PM

$CTXR You guys are being scammed by @TwongStocks Follow me at $IMMX

2 · Reply

newtothis87 Mar. 11 at 4:01 PM

$CTXR anything come out of the chat? I was in a mtg

1 · Reply

Market Cap	21.53M
Revenue (ttm)	0.00
Net Income (ttm)	-37.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,318,600
Avg Vol	550,436
Day's Range	N/A - N/A
Shares Out	22.38M
Stochastic %K	72%
Beta	1.51
Analysts	Sell
Price Target	$6.00